TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Chronic renal anemia~* Continuous stable intravenous or subcutaneous maintenance epoetin or darbepoetin therapy during previous month~* Regular long-term hemodialysis therapy with the same mode of dialysis for the previous 3 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Poorly controlled hypertension~* Significant acute or chronic bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera in Renal Anemia (Type: EXPERIMENTAL): Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fathers and Late Preterm Babies Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Fathers - first-time father, 18 years or older, speak and read English, live with the child's other parent, live within one hours' drive of the university~* Infants - born between 34 weeks and 0 days and 36 weeks and 6 days gestation, singleton~Exclusion Criteria:~* Fathers - known addictions~* Infants - one of a multiple birth, required assisted ventilation, had culture-proven sepsis, major surgical procedure, identified major congenital anomalies, chromosomal anomalies, intracranial hemorrhage, neurologic disorder, or perinatal asphyxia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A Teal (Type: EXPERIMENTAL): Standard Dose - Two intervention home visits (at 4 and 6 months of age)
- Group B Purple (Type: EXPERIMENTAL): High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
- Group C Yellow (Type: SHAM_COMPARATOR): Comparison Group - One home visit, information only (at 4 months of age)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of CP-CML with cytogenetic confirmation of Philadelphia (Ph) chromosome~* Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR are also eligible~* WHO performance status 0-2~* Laboratory assessments within normal limits~* Written informed consent prior to any study procedures being performed~Exclusion Criteria:~* Known impaired cardiac function~* History of acute or chronic pancreatitis~* Impaired gastrointestinal function or disease that may alter the absorption of study drug~* Concomitant medications with potential QT prolongation, or known to interact with CYP450 isoenzymes (CYP3A4, CYP2C9, and CYP2C8)~* Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy~* Patients who are pregnant or breast feeding, or females of reproductive potential not employing an effective method of birth control. Female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18-40 year old women~* BV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months~* Willing to use the NuvaRing as directed~* Not intending or wishing to become pregnant over the course of the study~* Capable of providing written informed consent~Exclusion Criteria:~* Current pregnancy~* Desire/intent to become pregnant over the course of the study~* Women who are less than 6 weeks postpartum~* Contraindications to hormonal contraceptive use per package insert, including history of deep vein thrombosis, smoking in women older than 35 years~* Current IUD~* Unable to comprehend consent material because of language barrier or psychological difficulty

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Cyclic NuvaRing CVR Use (Type: ACTIVE_COMPARATOR): CVR use for 3 weeks, remove for 1 week, then replace
- Continuous NuvaRing CVR Use (Type: EXPERIMENTAL): CVR use for 4 weeks, then replace

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition~Exclusion Criteria:~* Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- TRI102 (Type: EXPERIMENTAL): Active, amphetamine extended-release oral suspension
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Working Memory Training on Delay Discounting Among Cigarette Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria: To be included in this study, a participant must be 18 years of age or older, who have smoked at least four cigarettes per day for at least 6 months, are interested in quitting cigarette smoking, are at or below the federal poverty line based on persons in family/household and annual household income:~* 1 -- $12,880~* 2 -- $17,420~* 3 -- $21,960~* 4 - $26,500~* 5 -- $31,040~* 6 -- $35,580~* 7 -- $40,120~* 8 -- $44,660~* 9 - add $4,540 for each additional person,~OR they or their child(ren) utilize a federal program for low-income individuals, and are willing to participate in a 5-week working memory training program as a pretreatment adjunct to behavioral group + nicotine replacement therapy (NRT; via nicotine patches).~Exclusion criteria: Participants must not indicate a severe substance use disorder according to the DSM-V with any substance other than tobacco or have any significant medical or psychiatric condition. Such conditions could include traumatic brain injury, dementia, significant learning disability, or psychotic symptoms. Participants must be at least at a 5th-grade reading level. In case that participants are excluded, they will be provided with resources in the community and provided with contact information for the Kansas Tobacco Quitline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Working Memory Training (Active Training) + Behavioral Intervention (Type: EXPERIMENTAL): Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
- Control Training (CT) + Behavioral Intervention (Type: ACTIVE_COMPARATOR): Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-65 years old~* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder~* The patient's current depressive episode must be at least 8 weeks in duration~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control~* Patients with a history of meeting DSM-IV-TR criteria for:~  * any manic or hypomanic episode~ * schizophrenia or any other psychotic disorder~ * obsessive-compulsive disorder~* Patients who are considered a suicide risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
- 2 (Type: EXPERIMENTAL): 80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
- 3 (Type: EXPERIMENTAL): 120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
- 4 (Type: PLACEBO_COMPARATOR): Matching placebo capsules, oral administration, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects ≥ 18 to ≤ 75 years of age will be screened for eligibility.~* Eligible adult patients will have histologically proven sarcoidosis, diagnosed at least 6 months before screening, evidence of parenchymal disease on chest radiograph, an FVC between 50% and 85% of the predicted value, and a Medical Research Council dyspnea score (47) of at least grade 1.~* Patients must have been treated with at least 10 mg/day of prednisone or equivalent or one or more immunomodulating agents (hydroxychloroquine, methotrexate, azathioprine, leflunomide) for \>3 months before screening.~* Doses of these medications must be stable for at least 1 month before study entry.~* During the study, background medication regimen and doses are to remain stable.~Exclusion Criteria:~* active tobacco smoking or use of smokeless tobacco products containing nicotine,~* active cardiac or central nervous system disease,~* history of adverse reaction to nicotine or nicotine-containing products,~* patients with extensive irreversible pulmonary fibrosis (based upon lung biopsy or high resolution CT scan criterion) or inability to provide consent.~The subject will be excluded if they have a smoking history of greater than 20 pack years, or a diagnosis of other significant respiratory disorder other, than sarcoidosis that, in the opinion of the investigator, would complicate the evaluation of response to treatment; or, history of substance abuse (drugs or alcohol) within 3 years prior to screening or other circumstances (e.g., psychiatric disease) that could interfere with the subject's adherence to protocol requirements or increase their risk of drug (nicotine) dependence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Habitrol Nicotine patch - 7,14,21 mg patches Qd
- Control (Type: PLACEBO_COMPARATOR): Placebo patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient must have a confirmed diagnosis of alpha-mannosidosis as defined by alpha-mannosidase activity \< 10% of normal activity in blood leukocytes~2. The patient must have an age at the time of screening ≥ 5 year and ≤ 20 years~3. The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography).~4. The patient must have the ability to mentally cooperate in the cognitive and motor function tests~5. The patient must have the ability to hear and follow a request. Hearing aids can be worn.~6. Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)~7. The patient and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~1. The patient cannot walk without support.~2. Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis~3. History of bone marrow transplantation~4. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~5. Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial~6. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial~7. Pregnancy~8. Psychosis within the last 3 months

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Lamazym 6.25 (Type: EXPERIMENTAL): None
- Lamazym 12.5 (Type: EXPERIMENTAL): None
- Lamazym 25 (Type: EXPERIMENTAL): None
- Lamazym 50 (Type: EXPERIMENTAL): None
- Lamazym 100 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Term and near-term infants with a gestational age of more than 34 weeks~* Admitted to the Children's Hospital of Lucerne, Switzerland~* Suspected neonatal early-onset sepsis~* Antibiotic therapy~* Parental consent~Exclusion Criteria:~* Surgery in the first 3 days of life~* Severe congenital malformations~* Chromosomal abnormalities

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- Procalcitonin group (Type: EXPERIMENTAL): Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
- Standard group (Type: NO_INTERVENTION): Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 0.5M Na Lactate Solution in Acute Heart Failure (AHF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: more than 18 years~* Heart failure criteria:~Left heart failure: as evidenced by 2 out of 3:~* Left ventricular ejection fraction (LVEF) ≤ 40% and cardiac index ≤ 2.5 L/min/m2~* Acute pulmonary oedema of cardiac origin or mechanical ventilation (including CPAP/BIPAP) for respiratory failure of predominantly cardiac origin~* Need for inotropes/vasopressors for cardiac pump failure OR~Right heart failure: as evidenced by 1 out of 2:~* Bilateral leg oedema above ankles~* RV failure (low tricuspid annular plane systolic excursion (TAPSE), dilated floppy RV)~* Poor peripheral perfusion as evidenced by 2 out of 3:~Cold mottled skin Low urine output Acutely clouded sensorium/poor mentation~* Consent obtained from patient or patient's next of kin.~Exclusion Criteria:~* Hypernatremia: \[Na\] \>145 mmol/L~* Diagnosed hypertrophic obstructive cardiomyopathy~* Uncorrected severe valvular heart disease~* Documented third degree heart block, sustained ventricular tachycardia~* Documented cardiac tamponade~* Septic shock~* Acute respiratory distress syndrome (ARDS)~* Moribund patients likely to die before 24h~* Patients with major diseases of limited prognosis such as end stage cancer,end-stage liver failure, end stage dialysis dependent renal failure~* Patients with absolute indication for acute hemodialysis/hemofiltration (pH, K, urea \> 35 mmol/L, severe fluid overload in the presence of oliguria \< 200 mL/6h.~* Known pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5M Sodium lactate (Type: EXPERIMENTAL): A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
- Hartmann's solution (Type: ACTIVE_COMPARATOR): Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine Infusion in Radical Cystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 45-75 yr ASA class I,II, and III Elective radical cystectomy~Exclusion Criteria:~* Allergy to the study medication, pre-existing chronic pain at any site requiring treatment, Psychiatric disease, hepatic or renal impairment, seizure disorder requiring medication within the previous 2 years

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): IV Lidocaine infusion
- Control (Type: PLACEBO_COMPARATOR): IV normal saline infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who received Nexavar for unresectable hepatocellular carcinoma~Exclusion Criteria:~* Patients who are contraindicated based on the product label

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete